学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

森下総司（モリシタソウジ）

研究テーマ	疾患関連遺伝子の探索と診断システム開発
研究業績（論文）	発表論文 2023年　　Morishita S. and Komatsu N. Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms. Int J Mol Sci 4(16):13008. 　　Edahiro Y, Ochiai T, Hashimoto Y, Morishita S, Shirane S, Inano T, Furuya C, Koike M, Noguchi M, Usuki K, Shiratsuchi M, Nakajima K, Ohtsuka E, Tanaka H, Kawata E, Nakamae M, Ueda Y, Aota Y, Sugita Y, Ohara S, Yamasaki S, Asagoe K, Yoshida S, Yamanouchi J, Suzuki S, Kondo T, Kanisawa Y, Toyama K, Omura H, Mizuchi D, Sakamaki S, Ando M, Komatsu N. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Int J Hematol 118(1):47-53. 　　Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N. MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology 28(1):2229131. 　　Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, and Komatsu N. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis 2023; 55(2): 263-272. 　　Liu C, Imai M, Edahiro Y, Mano S, Takei H, Nudejima M, Kurose A, Morishita S, Ando M, Tsuneda S, Araki M, and Komatsu N. Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. Exp Hematol 2023; 118: 12-20. 　　Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, Inano T, Yasuda H, Ando M, Araki M, and Komatsu N. Non-driver mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. Eur J Haematol 2023; 110(2): 131-136. 2022年　　Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y, Nakamura H, Nakayama T, and Komatsu N. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol 2022; 1-8. 　　Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Tomoiku T, and Kitamura T. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nature Commun 2022; 13: 271. 　　De Marchi F, Okuda M, Morishita S, Imai M, Baba T, Horino M, Mori Y, Furuya C, Ogata S, Yang Y, Ando J, Ando M, Araki M, and Komatsu N. Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res 2022; 119: 106883. 　　Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, and Komatsu N. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients. Internal Med 2022; 61(22): 3323-3328. 　　Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, Ochiai T, Shirane S, Hashimoto Y, Yasuda H, Ando J, Ando M, and Komatsu N. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. Cancer Med 2022; 00: 1-11. 　　Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, Ochiai T, Shirane S, Ando J, and Komatsu N. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology 2022; 27(1): 157-166. 2021年　　Baba T, Yoshida T, Tanabe Y, Nishimura T, Morishita S, Gotoh A, Hanayama R, and Mukaida N. Cytoplasmic DNA accumulation preferentially triggers cell death of myeloid leukemia cells by interacting with intracellular DNA sensing pathway. Cell Death Dis. 2021; 12(4): 322 　　Morishita S, Ochiai T, Misawa K, Osaga S, Inano T, Fukuda Y, Edahiro Y, Ohsaka A, and Komatsu N. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. Int J Hematol 2021; 113: 500-507 　　Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki Y, Ito M, Araki M, and Komatsu N. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci 2021; 112: 884-892 　　Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, Ando J, Tsutsui M, Itakura A, and Komatsu N. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2021; 113(1): 106-111 　　Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Morishita S, Komatsu N, Ikeda K, and Takeishi Y. Crucial role of hematopoietic JAK2V617F mutation in the development of aortic aneurysms. Haematologica 2021; 106(7): 1910-1922 2020年　　Tanabe Y, Kawamoto S, Takaku T, Morishita S, Hirao A, Komatu N, Hara E, Mukaida N, and Baba T. Expanding senescent megakaryocyte-lineage cells maintain CML cell leukemogenesis. Blood Adv 2020; 4(24): 6175-6188 2019年　　Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sano K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, and Kimura F. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood 2019; 134(10): 814-825 　　Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, and Komatsu N. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 2019; 104(11): e506-e509 　　Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, and Komatsu N. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythemia vera. Br J Haematol 2019; 187(1): e27-e31 　　Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, and Komatsu N. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol 2019; 102(6): 516-520 2018年　　Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, Yang H, Matsushita H, Hanami T, Yamanaka Y, Okuzawa A, Horii T, Hayashizaki Y, and Ohsaka A. Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes. PLos ONE 2018; 13(10): e0202429 　　Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, and Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol 2018; 181(6): 791-802 　　Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018; 107(6): 673-680 　　Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: a comparison in a large-scale cohort. Eur J Haematol 2018; 100(6): 544-549 2017年　　Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol 2017; 92(7): E128-130 　　Ai T, Yuri M, Tabe Y, Kakimoto A, Morishita S, Tsuchiya K, Takamochi K, Kodama Y, Takahashi F, Shigeki M, Horii T, Suzuki K, Takahashi K, Miida T, and Ohsaka A. Comparison of the analytical performance between cobas EGFR assay and PCR-Clamp method in the detection of EGFR mutations in Japanese non-small cell lung cancer patients. Clin Lab 2017; 63(5): 1021-1026 　　Ueda K, Ikeda K, Ikezoe T, Harada SK, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima NA, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, and Takeishi Y. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv 2017; 1:1001-1015 　　Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, and Takeishi Y. The Amelioration of myelofibrosis with thrombocytopenia by a JAK1/2 inhibitor, Ruxolitinib, in a post-polycythemia vera myelofibrosis patient with a JAK2 exon 12 mutation. Internal Med 2017; 56(13): 1705-1710 　　Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, and Komatsu N. Histone Acetyltransferase p300/CREB-binding protein-associated factor (PCAF) is required for all-trans-retinoic acid-induced granurocytic differentiation in leukemia cells. J Biol Chem 2017; 292(7): 2815-2829 　　Mohammad S, Gotoh A, Morishita S, and Komatsu N. Imatinib-sensitive myeloid neoplasm with low allele burden of FIP1L1-PDGFRA fusion gene in an elderly patient. Geriatr Gerontol Int 2017; 16(12): 1346-1348 　　Watanabe N, Yasuda H, Morishita S, Aota Y, Tomomatsu J, Tanaka M, Ohsaka A, and Komatsu N. Ritchter’s syndrome with hypercalcemia induced by tumor-associated production of parathroid hormone-related peptide. Case Rep Oncol 2017; 10(1): 123-126 2016年　　Baba T, Tanabe Y, Yoshikawa S, Yamanishi Y, Morishita S, Komatsu N, Karasuyama H, Hirao A, and Mukaida N. MIP-1a/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesiss of chronic myeloid leukemia in mice. Blood 2016; 127(21): 2607-2617 　　Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, and Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127(10): 1307-1316 　　Liew EL, Araki M, Hironaka Y, Mori S, Tan TZ, Morishita S, Edahiro Y, Ohsaka A, and Komatsu N. Identification of AIM2 as downstream target of JAK2V617F. Exp Hematol Oncol 2016; 5: 2

研究テーマ

疾患関連遺伝子の探索と診断システム開発

研究業績（論文）

発表論文
2023年
　　Morishita S. and Komatsu N. Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms. Int J Mol Sci 4(16):13008.
　　Edahiro Y, Ochiai T, Hashimoto Y, Morishita S, Shirane S, Inano T, Furuya C, Koike M, Noguchi M, Usuki K, Shiratsuchi M, Nakajima K, Ohtsuka E, Tanaka H, Kawata E, Nakamae M, Ueda Y, Aota Y, Sugita Y, Ohara S, Yamasaki S, Asagoe K, Yoshida S, Yamanouchi J, Suzuki S, Kondo T, Kanisawa Y, Toyama K, Omura H, Mizuchi D, Sakamaki S, Ando M, Komatsu N. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Int J Hematol 118(1):47-53.
　　Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N. MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology 28(1):2229131.
　　Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, and Komatsu N. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis 2023; 55(2): 263-272.
　　Liu C, Imai M, Edahiro Y, Mano S, Takei H, Nudejima M, Kurose A, Morishita S, Ando M, Tsuneda S, Araki M, and Komatsu N. Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. Exp Hematol 2023; 118: 12-20.
　　Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, Inano T, Yasuda H, Ando M, Araki M, and Komatsu N. Non-driver mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. Eur J Haematol 2023; 110(2): 131-136.

2022年
　　Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y, Nakamura H, Nakayama T, and Komatsu N. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol 2022; 1-8.
　　Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Tomoiku T, and Kitamura T. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nature Commun 2022; 13: 271.
　　De Marchi F, Okuda M, Morishita S, Imai M, Baba T, Horino M, Mori Y, Furuya C, Ogata S, Yang Y, Ando J, Ando M, Araki M, and Komatsu N. Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res 2022; 119: 106883.
　　Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, and Komatsu N. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients. Internal Med 2022; 61(22): 3323-3328.
　　Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, Ochiai T, Shirane S, Hashimoto Y, Yasuda H, Ando J, Ando M, and Komatsu N. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. Cancer Med 2022; 00: 1-11.
　　Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, Ochiai T, Shirane S, Ando J, and Komatsu N. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology 2022; 27(1): 157-166.

2021年
　　Baba T, Yoshida T, Tanabe Y, Nishimura T, Morishita S, Gotoh A, Hanayama R, and Mukaida N. Cytoplasmic DNA accumulation preferentially triggers cell death of myeloid leukemia cells by interacting with intracellular DNA sensing pathway. Cell Death Dis. 2021; 12(4): 322
　　Morishita S, Ochiai T, Misawa K, Osaga S, Inano T, Fukuda Y, Edahiro Y, Ohsaka A, and Komatsu N. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. Int J Hematol 2021; 113: 500-507
　　Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki Y, Ito M, Araki M, and Komatsu N. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci 2021; 112: 884-892
　　Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, Ando J, Tsutsui M, Itakura A, and Komatsu N. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2021; 113(1): 106-111
　　Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Morishita S, Komatsu N, Ikeda K, and Takeishi Y. Crucial role of hematopoietic JAK2V617F mutation in the development of aortic aneurysms. Haematologica 2021; 106(7): 1910-1922

2020年
　　Tanabe Y, Kawamoto S, Takaku T, Morishita S, Hirao A, Komatu N, Hara E, Mukaida N, and Baba T. Expanding senescent megakaryocyte-lineage cells maintain CML cell leukemogenesis. Blood Adv 2020; 4(24): 6175-6188

2019年
　　Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sano K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, and Kimura F. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood 2019; 134(10): 814-825
　　Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, and Komatsu N. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 2019; 104(11): e506-e509
　　Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, and Komatsu N. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythemia vera. Br J Haematol 2019; 187(1): e27-e31
　　Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, and Komatsu N. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol 2019; 102(6): 516-520

2018年
　　Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, Yang H, Matsushita H, Hanami T, Yamanaka Y, Okuzawa A, Horii T, Hayashizaki Y, and Ohsaka A. Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes. PLos ONE 2018; 13(10): e0202429
　　Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, and Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol 2018; 181(6): 791-802
　　Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018; 107(6): 673-680
　　Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: a comparison in a large-scale cohort. Eur J Haematol 2018; 100(6): 544-549

2017年
　　Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, and Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol 2017; 92(7): E128-130
　　Ai T, Yuri M, Tabe Y, Kakimoto A, Morishita S, Tsuchiya K, Takamochi K, Kodama Y, Takahashi F, Shigeki M, Horii T, Suzuki K, Takahashi K, Miida T, and Ohsaka A. Comparison of the analytical performance between cobas EGFR assay and PCR-Clamp method in the detection of EGFR mutations in Japanese non-small cell lung cancer patients. Clin Lab 2017; 63(5): 1021-1026
　　Ueda K, Ikeda K, Ikezoe T, Harada SK, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima NA, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, and Takeishi Y. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv 2017; 1:1001-1015
　　Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, and Takeishi Y. The Amelioration of myelofibrosis with thrombocytopenia by a JAK1/2 inhibitor, Ruxolitinib, in a post-polycythemia vera myelofibrosis patient with a JAK2 exon 12 mutation. Internal Med 2017; 56(13): 1705-1710
　　Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, and Komatsu N. Histone Acetyltransferase p300/CREB-binding protein-associated factor (PCAF) is required for all-trans-retinoic acid-induced granurocytic differentiation in leukemia cells. J Biol Chem 2017; 292(7): 2815-2829
　　Mohammad S, Gotoh A, Morishita S, and Komatsu N. Imatinib-sensitive myeloid neoplasm with low allele burden of FIP1L1-PDGFRA fusion gene in an elderly patient. Geriatr Gerontol Int 2017; 16(12): 1346-1348
　　Watanabe N, Yasuda H, Morishita S, Aota Y, Tomomatsu J, Tanaka M, Ohsaka A, and Komatsu N. Ritchter’s syndrome with hypercalcemia induced by tumor-associated production of parathroid hormone-related peptide. Case Rep Oncol 2017; 10(1): 123-126

2016年
　　Baba T, Tanabe Y, Yoshikawa S, Yamanishi Y, Morishita S, Komatsu N, Karasuyama H, Hirao A, and Mukaida N. MIP-1a/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesiss of chronic myeloid leukemia in mice. Blood 2016; 127(21): 2607-2617
　　Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, and Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127(10): 1307-1316
　　Liew EL, Araki M, Hironaka Y, Mori S, Tan TZ, Morishita S, Edahiro Y, Ohsaka A, and Komatsu N. Identification of AIM2 as downstream target of JAK2V617F. Exp Hematol Oncol 2016; 5: 2

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

森下 総司（モリシタ ソウジ）

森下総司（モリシタソウジ）